Nuformix plc (LON:NFX – Get Free Report)’s stock price fell 6.5% during mid-day trading on Wednesday . The stock traded as low as GBX 0.16 and last traded at GBX 0.16. 3,252,227 shares changed hands during trading, a decline of 90% from the average daily volume of 31,894,922 shares. The stock had previously closed at GBX 0.17.
Nuformix Stock Down 5.9%
The stock has a market cap of £4.18 million, a price-to-earnings ratio of -5.46 and a beta of 1.54. The business has a 50-day moving average of GBX 0.18 and a 200-day moving average of GBX 0.21.
Nuformix (LON:NFX – Get Free Report) last issued its earnings results on Thursday, May 28th. The company reported GBX (0.02) EPS for the quarter.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.
See Also
- Five stocks we like better than Nuformix
- TSMC’s Price Hikes Could Show Which AI Chip Stocks Have Real Pricing Power
- Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off?
- Microsoft Earnings Are Coming—But Azure and CapEx Will Decide the Reaction
- Premium Retail’s Stress Test Is Separating Winners From Losers
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
